X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (139) 139
index medicus (129) 129
multiple sclerosis (105) 105
male (85) 85
clinical neurology (83) 83
female (78) 78
neurosciences (70) 70
adult (60) 60
middle aged (58) 58
neurology (54) 54
analysis (31) 31
young adult (31) 31
aged (30) 30
medicine & public health (27) 27
research (26) 26
care and treatment (25) 25
treatment outcome (22) 22
diagnosis (20) 20
disability (20) 20
fingolimod (20) 20
multiple sclerosis - drug therapy (20) 20
multiple sclerosis, relapsing-remitting - drug therapy (20) 20
safety (20) 20
drug therapy (19) 19
natalizumab (19) 19
animals (18) 18
glatiramer acetate (18) 18
therapy (18) 18
baroreflex sensitivity (17) 17
blood pressure (17) 17
parkinson's disease (17) 17
pharmacology & pharmacy (17) 17
autonomic nervous system (16) 16
clinical trials (16) 16
disease (16) 16
immunology (16) 16
immunosuppressive agents - therapeutic use (16) 16
multiple system atrophy (16) 16
hypertension (15) 15
multiple-sclerosis (15) 15
oral fingolimod (15) 15
quality of life (15) 15
adolescent (14) 14
patients (14) 14
psychiatry (14) 14
time factors (14) 14
experimental autoimmune encephalomyelitis (13) 13
management (13) 13
neurology. diseases of the nervous system (13) 13
original research (13) 13
autonomic dysfunction (12) 12
disease progression (12) 12
double-blind (12) 12
double-blind method (12) 12
germany (12) 12
heart-rate-variability (12) 12
inflammation (12) 12
peripheral vascular disease (12) 12
studies (12) 12
alemtuzumab (11) 11
electrocardiography (11) 11
fatigue (11) 11
fty720 (11) 11
clinical medicine (10) 10
health aspects (10) 10
heart rate (10) 10
multicenter (10) 10
prospective studies (10) 10
quality-of-life (10) 10
research article (10) 10
trial (10) 10
autonomic nervous system - physiopathology (9) 9
autonomic nervous system diseases - etiology (9) 9
baroreflex - physiology (9) 9
blood pressure - physiology (9) 9
depression (9) 9
eeg (9) 9
heart rate variability (9) 9
impact (9) 9
long-term (9) 9
multidisciplinary sciences (9) 9
neuroradiology (9) 9
neuroscience (9) 9
parkinson disease - complications (9) 9
parkinson disease - physiopathology (9) 9
pharmacology/toxicology (9) 9
risk (9) 9
usage (9) 9
abridged index medicus (8) 8
aged, 80 and over (8) 8
article (8) 8
central-nervous-system (8) 8
cohort studies (8) 8
complications and side effects (8) 8
disease-modifying therapies (8) 8
efficacy (8) 8
fingolimod hydrochloride - therapeutic use (8) 8
heart beat (8) 8
mechanisms (8) 8
neuroimaging (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


DNP - Der Neurologe & Psychiater, ISSN 1616-2455, 10/2019, Volume 20, Issue 5, pp. 33 - 36
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 05/2019, p. 135245851985426
Journal Article
DNP - Der Neurologe & Psychiater, ISSN 1616-2455, 08/2019, Volume 20, Issue 4, pp. 15 - 15
Journal Article
Neurodegenerative disease management, 04/2019, Volume 9, Issue 2s, p. 1
Proceedings of an Almirall-sponsored satellite symposium held at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis... 
Journal Article
Journal Article
Current Pharmaceutical Design, ISSN 1381-6128, 10/2012, Volume 18, Issue 29, pp. 4485 - 4488
Psychoneuroimmunology is a relatively young field of research that investigates interactions between central nervous and immune system. The brain modulates the... 
Autoimmune diseases
Journal Article
Journal of neurology, ISSN 0340-5354, 07/2019, pp. 1 - 12
Secondary progressive multiple sclerosis (SPMS) is the second most common form of multiple sclerosis (MS). One in two relapse remitting multiple sclerosis... 
Multiple sclerosis | Diagnosis
Journal Article
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 10/2018, Volume 89, Issue 10, pp. A27 - A27
ObjectivesPresent first interim results of PANGAEA 2.0 including effectiveness data of patients switching from other oral disease modifying therapies (oDMTs;... 
Journal Article
Journal of the Neurological Sciences, ISSN 0022-510X, 2011, Volume 311, Issue 1, pp. S48 - S52
Journal Article
Neurodegenerative disease management, 2015, Volume 5, Issue 6, pp. 51 - 53
Journal Article
Therapeutic Advances in Neurological Disorders, ISSN 1756-2856, 10/2017, Volume 10, Issue 10, pp. 343 - 359
Alemtuzumab is a humanized monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (RRMS), given as two annual courses on five... 
mechanism of action | long-term efficacy | alemtuzumab | real-world experience | multiple sclerosis | long-term safety | BRAIN ATROPHY | DENDRITIC CELLS | PLACEBO-CONTROLLED PHASE-3 | SECONDARY | NATALIZUMAB | INTERFERON-BETA | ORAL BG-12 | CLINICAL NEUROLOGY | DEMYELINATION | DISEASE | REGULATORY T-CELLS | Review
Journal Article
Current Pharmaceutical Design, ISSN 1381-6128, 2012, Volume 18, Issue 29, pp. 4485 - 4488
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2017, Volume 16, Issue 4, pp. 271 - 281
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 12/2017, Volume 88, Issue Suppl 1, pp. A41 - A41
BackgroundIn the SELECT and DECIDE studies, daclizumab HYP (daclizumab) showed efficacy in RRMS patients with highly active disease (HAD;≥2 relapses in... 
Journal Article
Journal Article
InFo Neurologie & Psychiatrie, ISSN 1437-062X, 11/2015, Volume 17, Issue 11, pp. 31 - 32
Journal Article